ReviewBest practice & research. Clinical obstetrics & gynaecology2012
Overview of microbicides for the prevention of human immunodeficiency virus.
Review in Best practice & research. Clinical obstetrics & gynaecology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 41 citations in OpenAlex.
- Self-reported removal and expulsion of the dapivirine vaginal ring: qualitative reports from female ring users and their male partners in the Ring Study (IPM 027).BMC public health · 2024Article
- Lactic acid bacterial surface display of scytovirin inhibitors for anti-ebolavirus infection.Frontiers in microbiology · 2023Article
- Dapivirine Bioadhesive Vaginal Tablets Based on Natural Polymers for the Prevention of Sexual Transmission of HIV.Polymers · 2019Article
- Mucus and Mucins: do they have a role in the inhibition of the human immunodeficiency virus?Virology journal · 2017Review
- Abolishing HIV-1 infectivity using a polypurine tract-specific G-quadruplex-forming oligonucleotide.BMC infectious diseases · 2016Article
- Rice endosperm is cost-effective for the production of recombinant griffithsin with potent activity against HIV.Plant biotechnology journal · 2016Article
- Formulation and characterization of polymeric films containing combinations of antiretrovirals (ARVs) for HIV prevention.Pharmaceutical research · 2015Article
- Article
- Prophylactic treatment with a novel bioadhesive gel formulation containing aciclovir and tenofovir protects from HSV-2 infection.The Journal of antimicrobial chemotherapy · 2014Article
- Biodistribution and pharmacokinetics of dapivirine-loaded nanoparticles after vaginal delivery in mice.Pharmaceutical research · 2014Article
- A review of nanotechnological approaches for the prophylaxis of HIV/AIDS.Biomaterials · 2013Review
- In vivo anti-herpes simplex virus activity of a sulfated derivative of Agaricus brasiliensis mycelial polysaccharide.Antimicrobial agents and chemotherapy · 2013Article
- Evaluation of the lymphocyte trafficking drug FTY720 in vaginal tissues.Journal of medical primatology · 2013Article
- Development and evaluation of a thermosensitive vaginal gel containing raltegravir+efavirenz loaded nanoparticles for HIV prophylaxis.Antiviral research · 2012Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 2 countries.
Funding
Abstract
Human immunodeficiency virus (HIV) prevention tools that women can use and control are urgently needed. Microbicides are chemical products applied to the vagina or rectum to prevent the sexual transmission of HIV. Four classes of candidate microbicides have been tested to date: those that (1) enhance the natural defences in the vagina to inactivate HIV; (2) inactivate HIV in the vagina; (3) prevent HIV from attaching to, and fusing with, the host cells; and (4) prevent HIV from replicating in genital tract host cells. Despite numerous disappointing efficacy trial results over the past 20 years, substantial progress is now being made in microbicide development after the release of the CAPRISA 004 trial, which provided proof-of-concept that topical antiretroviral microbicides can prevent sexual transmission of HIV and herpes simplex type-2 infection. Microbicides, which fill an important gap for women-controlled prevention methods, have the potential to alter the course of the HIV pandemic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.